Injecting into the same spot over and over produces lipohypertrophy: the subcutaneous tissue thickens and absorption becomes erratic and unpredictable. That is the whole case for subcutaneous injection site rotation. The phenomenon has been documented for decades in insulin therapy, and its mechanism, repeated tissue trauma, does not depend on which substance is being administered.
What lipohypertrophy is and how to recognize it
Lipohypertrophy is a thickening of the subcutaneous fat in response to repeated injections in the same area. The tissue answers chronic mechanical trauma with adipocyte proliferation and fibrous deposits.
How it is detected:
- By touch, better than by sight. It feels firmer or rubbery than the tissue around it, sometimes with a poorly defined edge.
- Less sensitive to the needle, which creates a perverse incentive: the damaged area hurts less, so it keeps getting used and the damage gets worse.
- Visible in some cases as a slight bulge or raised patch under the skin.
The check is done with the palm and the fingertips, sweeping the area under light pressure and comparing it against tissue that has not been used.
The evidence comes from insulin
It helps to be precise about where this knowledge comes from, because the distinction matters.
Most of the research on lipohypertrophy comes from insulin therapy, where it has been studied for decades for a practical reason: it affects glycemic control directly. Prevalence studies in people who inject insulin daily report high figures, and the association with two factors is consistent:
- Not rotating injection sites.
- Reusing needles.
The finding with the biggest consequences is that absorption from lipohypertrophic tissue is erratic: not simply slower, but unpredictable. The same amount given at the same spot can be absorbed differently on different days. In insulin therapy that shows up as unexplained glycemic variability.
The honest limit of this evidence: it is established for insulin, given daily, over years. Research peptides have not been studied in that detail. What can reasonably be extrapolated is the mechanism: repeated tissue trauma does not care what was in the syringe. What cannot be claimed is the size of the effect for each compound, because nobody has measured it.
Rotation schemes
Subcutaneous injection site rotation works on two levels, and skipping the second one is the usual mistake.
Rotation between areas. Alternating between different anatomical regions.
Rotation within the area. Inside each region, no repeating a spot. The most common scheme divides the area mentally into quadrants and moves through them systematically, leaving at least one centimeter between consecutive punctures and coming back to the same point as late as possible.
A practical rule that works: sweep the area the way a page is read, left to right, then down one line, instead of picking "somewhere I have not used lately." Memory is a poor record; a systematic pattern is not.
Sites and absorption speed
Subcutaneous regions do not absorb equally. In the insulin therapy literature, the order of absorption speed is consistent:
| Site | Relative speed |
|---|---|
| Abdomen | Fastest |
| Arm (outer surface) | Intermediate |
| Thigh (anterolateral surface) | Slowest |
| Buttock (upper outer quadrant) | Slowest |
Two factors shift that speed noticeably: heat (a hot shower or a sauna raises local blood flow) and exercising the area, which does the same. Injecting into the thigh before a run is not the same as injecting into the thigh at rest.
The practical consequence is that switching areas introduces a variable. If rotation happens between different regions, absorption speed moves with it. That is why the standard advice in insulin therapy is to rotate within one area and save the change of region for when there is a reason.
When a site needs a rest
If palpation finds a hardened area, the established recommendation is to stop using it entirely until the tissue recovers its normal characteristics. That process is counted in months, not days, and depends on how long the area was in use.
Continuing to use a lipohypertrophic area because it hurts less is exactly what keeps it going.
What rotation does not solve
Subcutaneous injection site rotation prevents cumulative tissue damage and its effect on absorption. It does nothing about:
- Injection technique itself (depth, angle, speed), which is another variable.
- Needle reuse, an independent and additive risk factor. Choosing and using the syringe correctly covers that part.
- Compound stability, which depends on how the vial is stored.
And a warning worth repeating: describing general subcutaneous injection technique is handling information. Which compound, in what amount and how often is not a decision anyone should make by reading a blog.
Frequently asked questions
How long does an area with lipohypertrophy take to recover?
The insulin therapy literature describes recoveries counted in months, and they depend on how long the area was used and how severe the thickening is. There is no fixed timeline.
Does lipohypertrophy hurt?
Characteristically, no. It tends to be less sensitive than normal tissue, and that is precisely why it keeps getting used and the problem gets worse.
Is it the same as lipoatrophy?
No. Lipoatrophy is a loss of fat tissue, a depression in the skin, and it has a different, immune-mediated mechanism. Lipohypertrophy is the opposite: thickening from repeated trauma.
How often can I go back to the exact same spot?
Insulin therapy recommendations point to letting as much time as possible pass before repeating a specific spot, keeping each puncture at least one centimeter from the last. A systematic pattern within the area achieves that without having to remember anything.
References
- Frid AH, et al. New Insulin Delivery Recommendations. Mayo Clinic Proceedings, 2016;91(9):1231–1255. DOI: 10.1016/j.mayocp.2016.06.010
- Gentile S, et al. Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? Diabetes Therapy, 2016;7(3):401–409. DOI: 10.1007/s13300-016-0187-6
- Blanco M, et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism, 2013;39(5):445–453. DOI: 10.1016/j.diabet.2013.05.006
- Frid A, Linde B. Where do lipodystrophic patients inject their insulin? British Medical Journal, 1986;293(6544):459. PMC1341163
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.